MONT-SAINT-GUIBERT, Belgium, March 24, 2023 (GLOBE NEWSWIRE) – Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the “Company”), a biotechnology company focused on innovative technologies for Chimeric Antigen Receptor (CAR) T-cell therapies, is pleased to announce the appointment of Georges Rawadi as its new Chief Executive Officer (CEO), effective March 23, 2023. to announce , effective April 17, 2023. Michel Lussier will continue as interim CEO until April 17 to facilitate the transition.

Georges Rawadi is a seasoned executive with over 20 years of Pharma/Biotech experience as Research Leader, Business Developer, CEO and Board Member. He spent four years at Celyad Oncology (2014-2018) as Vice-President Business Development & Intellectual Property (“BD & IP”) and has in-depth knowledge of both the company and the CAR-T space. Georges Rawadi has a real passion for finding and creating new business opportunities.

Georges Rawadi currently holds a number of board and consulting positions in the biotechnology industry. Most recently he was CEO and board member of Ysopia Bioscience (France), Vice President BD & IP of Celyad Oncology and Vice President Business Development of Cellectis (France – Nasdaq listed company).

Georges Rawadi holds a masters degree in biochemistry, a masters degree in microanalysis, a Ph.D. in Microbiology and an Executive Masters in Management and Strategy in the Healthcare Industry.

Hilde Windels, CEO, commented: “It is with great excitement that we announce that Georges has been appointed as our new CEO. His deep expertise in the CAR-T space and significant BD and IP expertise are major assets that will help Celyad Oncology excel in its next phase of growth. We congratulate Georges and wish him all the best in his new role.”

Georges Rawadi added: “I am passionate about the space Celyad Oncology is in and a firm believer in the value of its IP fortune and its efforts to overcome the current limitations of…